Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Extension Study of Litifilimab in Systemic Lupus Erythematosus
NCT05352919Phase 3Enrolling by invitation
- Sponsor
- Biogen
- Start
- Jun 2022
- Primary completion
- May 2032
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 28
01
Overview
A Phase 3 trial of litifilimab in systemic lupus erythematosus (SLE), sponsored by Biogen. Started Jun 2022; status: enrolling by invitation.
02
Drugs
litifilimab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05352919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05352919.